Clinical Significance of Microsatellite Instability in Sporadic Epithelial Ovarian Tumors.
10.3349/ymj.2008.49.2.272
- Author:
Bo Sung YOON
1
;
Young Tae KIM
;
Jae Hoon KIM
;
Sang Wun KIM
;
Eun Ji NAM
;
Nam Hoon CHO
;
Jae Wook KIM
;
Sunghoon KIM
Author Information
1. Department of Obstetrics and Gynecology, College of Medicine, Pochon CHA University, Seoul, Korea. shkim70@yuhs.ac
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Microsatellite instability;
polymerase chain reaction;
ovarian neoplasms
- MeSH:
DNA, Neoplasm/genetics;
Female;
Humans;
*Microsatellite Instability;
Ovarian Neoplasms/*genetics/*pathology;
Polymerase Chain Reaction
- From:Yonsei Medical Journal
2008;49(2):272-278
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: We evaluated the expression of microsatellite instability (MSI) in sporadic ovarian tumors using 5 standard and 9 new MSI markers to determine the clinical significance of MSI in sporadic epithelial ovarian tumors. MATERIALS AND METHODS: MSI was examined in 21 borderline and 25 malignant ovarian tumors. Polymerase chain reaction (PCR) was performed using the 5 markers recommended by the National Cancer Institute (NCI) for colon cancer and 9 additional markers. MSI was determined using fractional analysis by mixing the PCR products and size markers. RESULTS: Using the 5 conventional MSI markers, MSI was found in 4 of 46 (8.6%) ovarian tumors, including 2 of 21 (9.5%) borderline ovarian tumors and 2 of 25 (8%) malignant ovarian tumors. Using the 9 additional MSI markers, MSI was observed in 7 of 46 (15.2%) ovarian tumors, including 3 of 21 (14.3%) borderline ovarian tumors and 4 of 25 (16%) malignant ovarian tumors. There was no statistically significant difference between MSI and clinicopathological factors, including histology and stage, although there was a trend toward an increased incidence of MSI in the serous type. CONCLUSION: MSI was infrequent in ovarian tumors, including both borderline and malignant tumors. MSI was found to be uncommon in sporadic ovarian tumors, even by using additional MSI markers. The clinical significance of MSI is not strong in patients with sporadic ovarian tumors.
